Target, not a guess
A biologically validated disease driver identified through leading academic research.
SLHMs Therapeutics is developing targeted therapies for aggressive pediatric brain cancers, beginning with Group 3/4 medulloblastoma.
Humans are closely related to other primates, but a few important genetic differences helped shape the human brain. One of those differences may also play a role in medulloblastoma. That connection inspired the name Slightly Less Hairy Monkeys.
SLHMs Therapeutics is an early-stage biotechnology company dedicated to developing innovative therapeutic approaches for serious and underserved diseases. Guided by expertise in healthcare leadership, translational research, cancer genetics, and pediatric neuro-oncology, we are committed to advancing science-driven solutions that address significant unmet medical needs.
SLHMs Therapeutics is an early-stage biotechnology company dedicated to developing innovative treatments for children with aggressive brain cancer, particularly medulloblastoma, where significant unmet medical needs remain. Building on a validated biological mechanism, our team is moving urgently to translate promising scientific discoveries into therapies that have the potential to improve outcomes for children facing this devastating disease. Guided by expertise in healthcare leadership, translational research, cancer genetics, and pediatric neuro-oncology, we are committed to advancing science-driven solutions that address existing cancer and, ultimately, help prevent recurrence and metastatic spread.
A physician-scientist and biomedical innovator with decades of experience in translational research and the development of therapies for rare and complex diseases.
To urgently develop safe, science-driven treatments for children with medulloblastoma by advancing validated discoveries through responsible scientific and regulatory pathways.
A future where every child diagnosed with aggressive brain cancer has access to effective therapies that improve survival, prevent recurrence, and offer lasting hope.
A biologically validated disease driver identified through leading academic research.
Early preclinical studies support further optimization and development.
Relevant biological assays are available to support screening and optimization.
Disease-relevant cellular and in vivo models are available to support preclinical evaluation.
A clinically relevant biomarker strategy may support future patient selection.
Pediatric and rare-disease development pathways may create opportunities for focused regulatory engagement.
Some childhood brain tumors are especially difficult to treat because the cancer cells behave like immature cells that keep growing and dividing.
SLHMs Therapeutics is exploring a different approach: instead of only trying to kill tumor cells directly, we are studying ways to encourage them to mature.
When certain cells mature, they can lose the ability to keep rapidly dividing. In simple terms, our goal is to help cancer cells “grow up” so they are less able to fuel tumor growth.
Our work is focused on aggressive pediatric brain tumors where families urgently need better options. We are building on strong scientific insight, early laboratory research, and disease-relevant models to determine whether this approach can become a new kind of therapy.
Some cancer cells remain trapped in an immature state, allowing them to keep reproducing and sustaining tumor growth. SLHMs is developing a new approach designed to interrupt that cycle.
Our research focuses on a biological pathway that may encourage these cancer cells to mature, stop renewing themselves, or become more vulnerable to treatment. We are building from a research compound that has already demonstrated promising activity in laboratory studies.
Develop treatments that may improve outcomes while reducing the long-term burden of today’s aggressive therapies.
Our therapeutic approach is designed for delivery into the cerebrospinal fluid (CSF), enabling targeted treatment where pediatric brain tumors may spread.
Our work is centered on translating emerging biological insights into therapeutic opportunities while maintaining a disciplined and evidence-driven development strategy.
We focus on translating biological insight into therapeutic strategies, prioritizing programs with strong scientific rationale.
Disciplined, milestone-driven research and development designed for credibility with partners and reviewers.
Developing innovative therapies based on emerging scientific discoveries.
At SLHMs Therapeutics, our research is focused on developing innovative therapies for children with medulloblastoma, a rare and aggressive pediatric brain cancer. Our scientific approach is built on translational research, precision therapeutics, and cancer stem-cell biology, with the goal of transforming promising discoveries into meaningful treatments.
Certain cancer cells remain immature and continue reproducing, contributing to tumor growth and recurrence.
Our research has identified a biological pathway that may encourage these cells to mature or stop renewing themselves.
We have developed a promising research compound that demonstrates the potential of this therapeutic approach.
We are advancing this compound toward a safer, stronger, and patentable drug suitable for future clinical development.
Our treatment is being designed for delivery into the cerebrospinal fluid (CSF) to better target areas where metastatic disease may be present. Key Scientific Themes
SLHMs Therapeutics welcomes inquiries from investors, scientific collaborators, foundations, and strategic partners aligned with our mission to advance meaningful therapeutic development.
Connect with our team to explore collaborations, request support, or learn how SLHMs Therapeutics is driving meaningful therapeutic breakthroughs.
